Drug intelligence / Profile preview

BW-40202

Development stage: Phase 1
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Small Molecules
Administration: Subcutaneous

Overview

BW-40202 is an investigational drug currently in early clinical development. It is being evaluated in a Phase 1 clinical trial to assess its safety and effects in healthy adult volunteers. The drug is administered as a clear liquid via subcutaneous injection, with multiple dose levels being tested against placebo. As of now, detailed information about its mechanism of action, therapeutic class, or intended disease indications has not been disclosed publicly. The developer of BW-40202 is Shanghai Argo Biopharma.

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on BW-40202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-40202.

Explore the full profile